Archive
MyCelx ups full-year guidance as new order and equipment sale bring in US$2.7mln
MYCELX now expects full-year revenues to be in the range of US$16-17mln after the new order and equipment sale
Company
ReNeuron Group PLC
LON:RENE
ReNeuron Group PLC has developed a proprietary stem cell-derived, exosome-based, drug delivery platform with customisable cellular targeting capabilities for the delivery of complex drug modalities. Through the generation of several unique and scalable exosome producer cell lines, its CustomEX ™ platform can be optimised for specific tissues targets and payloads leading to improvements in therapeutic outcome and a reduction in off-target effects. ReNeuron offers a delivery mechanism for a variety of payloads such as siRNA, mRNA, proteins, small molecules and genes.
298 stories · page 9 of 15
ReNeuron wins £1.5mln to fund further development of its hRPC cell therapy candidate
ReNeuron’s human retinal progenitor cell (hRPC) therapy is being developed as a treatment for blindness-causing eye diseases such as retinitis pigmentosa
FTSE 100 closes in the black as Shire surges; tobacco stocks drift lower
Shire shares ended 5.89% up as the group received and rejected a takeover approach from Japan's Takeda Pharma
ReNeuron appoints new chief medical officer based in recently established US office
The AIM-listed firm said Dr Richard Beckham will replace Dr Julian Howell, who has left the company to pursue another opportunity
Archive
Proactive news snapshot: Galileo Resources, ValiRx, ITM Power …
A glance at some of the day's highlights from the Proactive Investors newswire
Archive
Proactive news snapshot: Instem, ANGLE, Stratex International …
A glance at some of the day's highlights from the Proactive Investors newswire
Milestone Group jumps as digital media company enters blockchain joint venture agreement
A look at some of the biggest risers and fallers in London on Monday
ReNeuron increases number of clinical sites in its PISCES III study
ReNeuron said it had taken the decision to increase the number of sites to ensure that patient recruitment targets in the study are met
FTSE 100 closes in red as pound firms but miners add support
Sterling added 0.01% against the Euro to 1.1434, while against the US dollar, it added 0.60% to 1.4232.
ReNeuron's CTX cells play a part in positive artificial nerve tissue study
This is the first time ReNeuron's CTX cells have been combined with an engineered support to guide nerve repair
Archive
Proactive news snapshot: Mosman Oil and Gas, Eland Oil & Gas, SDX Energy…
A glance at some of the day's highlights from the Proactive Investors newswire
Archive
Proactive news snapshot: ReNeuron, AFC Energy, Amur Minerals …
A glance at some of the day's highlights from the Proactive Investors newswire
Paternoster Resources hooks investors as it unveils bid to reduce costs
Proactive takes a look at the movers and shakers in London
ReNeuron Group presents positive stroke data to US conference
Lead investigator, Professor Keith Muir, updated on progress at the American Heart Association International Stroke Conference in Los Angeles
FTSE 100 clocks up 50 point gain despite strength of sterling
The dollar's revival did not last long, and although a weak dollar is regarded as being detrimental to the FTSE, the top-shares index still managed a 50 point gain
Archive
Proactive news snapshot: Kibo Mining, Mporium Group, Europa Oil & Gas ….
A glance at some of the day's highlights from the Proactive Investors newswire
Keller gains on US acquisition talks, also says Trump tax changes will benefit future earnings
Some of the main biggest risers and fallers in London on Friday
ReNeuron hopes share consolidation will improve the marketability and liquidity of the stock
The stem cell specialist said it wants to reduce its equity base by a factor of 100
FTSE 100 pops higher again to another record close
It was another quiet day in London but also another record close
Archive
Proactive news snapshot: Synairgen, Iofina, Atlantis Resources …
A glance at some of the day's highlights from the Proactive Investors newswire